Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline/Adolor Halt Entereg Bowel Dysfunction Program Due To Cardiovascular Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Top-line, 12-month Phase III safety data underscore CV concerns and raise new adverse event questions.

You may also be interested in...



Wyeth Plans Methylnaltrexone Studies In New Patient Populations

Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.

Wyeth Plans Methylnaltrexone Studies In New Patient Populations

Data from the three additional clinical studies would be used to expand labeling for the mu-opioid receptor antagonist following its approval, Progenics tells “The Pink Sheet” DAILY.

FDA Accepts Adolor/GSK Entereg Resubmission For Postoperative Ileus

Sponsors’ response to FDA clinical holds on the alvimopan program contain “substantially the same” information as the resubmitted NDA, Adolor tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel